Evaluation of live avian-human reassortant influenza A H3N2 and H1N1 virus vaccines in seronegative adult volunteers.
Identifieur interne : 000495 ( PubMed/Curation ); précédent : 000494; suivant : 000496Evaluation of live avian-human reassortant influenza A H3N2 and H1N1 virus vaccines in seronegative adult volunteers.
Auteurs : M H Snyder ; M L Clements ; R F Betts ; R. Dolin ; A J Buckler-White ; E L Tierney ; B R MurphySource :
- Journal of clinical microbiology [ 0095-1137 ] ; 1986.
Descripteurs français
- KwdFr :
- Adulte, Anticorps antiviraux (biosynthèse), Humains, Hémagglutinines virales (immunologie), Réplication virale, Sialidase (immunologie), Sous-type H1N1 du virus de la grippe A, Sous-type H3N2 du virus de la grippe A, Vaccins antiviraux (immunologie), Virus de la grippe A (croissance et développement), Virus de la grippe A (immunologie).
- MESH :
- biosynthèse : Anticorps antiviraux.
- croissance et développement : Virus de la grippe A.
- immunologie : Hémagglutinines virales, Sialidase, Vaccins antiviraux, Virus de la grippe A.
- Adulte, Humains, Réplication virale, Sous-type H1N1 du virus de la grippe A, Sous-type H3N2 du virus de la grippe A.
English descriptors
- KwdEn :
- Adult, Antibodies, Viral (biosynthesis), Hemagglutinins, Viral (immunology), Humans, Influenza A Virus, H1N1 Subtype, Influenza A Virus, H3N2 Subtype, Influenza A virus (growth & development), Influenza A virus (immunology), Neuraminidase (immunology), Viral Vaccines (immunology), Virus Replication.
- MESH :
- chemical , biosynthesis : Antibodies, Viral.
- chemical , immunology : Hemagglutinins, Viral, Neuraminidase, Viral Vaccines.
- growth & development : Influenza A virus.
- immunology : Influenza A virus.
- Adult, Humans, Influenza A Virus, H1N1 Subtype, Influenza A Virus, H3N2 Subtype, Virus Replication.
Abstract
An avian-human reassortant influenza A virus deriving its genes coding for the hemagglutinin and neuraminidase from the human influenza A/Washington/897/80 (H3N2) virus and its six "internal" genes from the avian influenza A/Mallard/NY/6750/78 (H2N2) virus (i.e., a six-gene reassortant) was previously shown to be safe, infectious, nontransmissible, and immunogenic as a live virus vaccine in adult humans. Two additional six-gene avian-human reassortant influenza viruses derived from the mating of wild-type human influenza A/California/10/78 (H1N1) and A/Korea/1/82 (H3N2) viruses with the avian influenza A/Mallard/NY/78 virus were evaluated in seronegative (hemagglutination inhibition titer, less than or equal to 1:8) adult volunteers for safety, infectivity, and immunogenicity to determine whether human influenza A viruses can be reproducibly attenuated by the transfer of the six internal genes of the avian influenza A/Mallard/NY/78 virus. The 50% human infectious dose was 10(4.9) 50% tissue culture infectious doses for the H1N1 reassortant virus and 10(5.4) 50% tissue culture infectious doses for the H3N2 reassortant virus. Both reassortants were satisfactorily attenuated with only 5% (H1N1) and 2% (H3N2) of infected vaccines receiving less than 400 50% human infectious doses developing illness. Consistent with this level of attenuation, the magnitude of viral shedding after inoculation was reduced 100-fold (H1N1) to 10,000-fold (H3N2) compared with that produced by wild-type virus. The duration of virus shedding by vaccines was one-third that of controls receiving wild-type virus. At 40 to 100 50% human infectious doses, virus-specific immune responses were seen in 77 to 93% of volunteers. When vaccinees who has received 10(7.5) 50% tissue culture infectious doses of the H3N2 vaccine were experimentally challenged with a homologous wild-type human virus only 2 of 19 (11%) vaccinees became ill compared with 7 of 14 (50%) unvaccinated seronegative controls ( P < 0.025; protective efficacy, 79%). Thus, three different virulent human influenza A viruses have been satisfactorily attenuated by the acquisition of the six internal genes of the avian influenza A/Mallard/NY/78 virus. The observation that this donor virus can reproducibly attenuate human influenza A viruses indicates that avian-human influenza A reassortants should be further studied as potential live influenza A virus vaccines.
PubMed: 3711273
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000495
Links to Exploration step
pubmed:3711273Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Evaluation of live avian-human reassortant influenza A H3N2 and H1N1 virus vaccines in seronegative adult volunteers.</title><author><name sortKey="Snyder, M H" sort="Snyder, M H" uniqKey="Snyder M" first="M H" last="Snyder">M H Snyder</name></author><author><name sortKey="Clements, M L" sort="Clements, M L" uniqKey="Clements M" first="M L" last="Clements">M L Clements</name></author><author><name sortKey="Betts, R F" sort="Betts, R F" uniqKey="Betts R" first="R F" last="Betts">R F Betts</name></author><author><name sortKey="Dolin, R" sort="Dolin, R" uniqKey="Dolin R" first="R" last="Dolin">R. Dolin</name></author><author><name sortKey="Buckler White, A J" sort="Buckler White, A J" uniqKey="Buckler White A" first="A J" last="Buckler-White">A J Buckler-White</name></author><author><name sortKey="Tierney, E L" sort="Tierney, E L" uniqKey="Tierney E" first="E L" last="Tierney">E L Tierney</name></author><author><name sortKey="Murphy, B R" sort="Murphy, B R" uniqKey="Murphy B" first="B R" last="Murphy">B R Murphy</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="1986">1986</date><idno type="RBID">pubmed:3711273</idno><idno type="pmid">3711273</idno><idno type="wicri:Area/PubMed/Corpus">000495</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000495</idno><idno type="wicri:Area/PubMed/Curation">000495</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000495</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Evaluation of live avian-human reassortant influenza A H3N2 and H1N1 virus vaccines in seronegative adult volunteers.</title><author><name sortKey="Snyder, M H" sort="Snyder, M H" uniqKey="Snyder M" first="M H" last="Snyder">M H Snyder</name></author><author><name sortKey="Clements, M L" sort="Clements, M L" uniqKey="Clements M" first="M L" last="Clements">M L Clements</name></author><author><name sortKey="Betts, R F" sort="Betts, R F" uniqKey="Betts R" first="R F" last="Betts">R F Betts</name></author><author><name sortKey="Dolin, R" sort="Dolin, R" uniqKey="Dolin R" first="R" last="Dolin">R. Dolin</name></author><author><name sortKey="Buckler White, A J" sort="Buckler White, A J" uniqKey="Buckler White A" first="A J" last="Buckler-White">A J Buckler-White</name></author><author><name sortKey="Tierney, E L" sort="Tierney, E L" uniqKey="Tierney E" first="E L" last="Tierney">E L Tierney</name></author><author><name sortKey="Murphy, B R" sort="Murphy, B R" uniqKey="Murphy B" first="B R" last="Murphy">B R Murphy</name></author></analytic><series><title level="j">Journal of clinical microbiology</title><idno type="ISSN">0095-1137</idno><imprint><date when="1986" type="published">1986</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Antibodies, Viral (biosynthesis)</term><term>Hemagglutinins, Viral (immunology)</term><term>Humans</term><term>Influenza A Virus, H1N1 Subtype</term><term>Influenza A Virus, H3N2 Subtype</term><term>Influenza A virus (growth & development)</term><term>Influenza A virus (immunology)</term><term>Neuraminidase (immunology)</term><term>Viral Vaccines (immunology)</term><term>Virus Replication</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adulte</term><term>Anticorps antiviraux (biosynthèse)</term><term>Humains</term><term>Hémagglutinines virales (immunologie)</term><term>Réplication virale</term><term>Sialidase (immunologie)</term><term>Sous-type H1N1 du virus de la grippe A</term><term>Sous-type H3N2 du virus de la grippe A</term><term>Vaccins antiviraux (immunologie)</term><term>Virus de la grippe A (croissance et développement)</term><term>Virus de la grippe A (immunologie)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="biosynthesis" xml:lang="en"><term>Antibodies, Viral</term></keywords><keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Hemagglutinins, Viral</term><term>Neuraminidase</term><term>Viral Vaccines</term></keywords><keywords scheme="MESH" qualifier="biosynthèse" xml:lang="fr"><term>Anticorps antiviraux</term></keywords><keywords scheme="MESH" qualifier="croissance et développement" xml:lang="fr"><term>Virus de la grippe A</term></keywords><keywords scheme="MESH" qualifier="growth & development" xml:lang="en"><term>Influenza A virus</term></keywords><keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Hémagglutinines virales</term><term>Sialidase</term><term>Vaccins antiviraux</term><term>Virus de la grippe A</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Influenza A virus</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Humans</term><term>Influenza A Virus, H1N1 Subtype</term><term>Influenza A Virus, H3N2 Subtype</term><term>Virus Replication</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adulte</term><term>Humains</term><term>Réplication virale</term><term>Sous-type H1N1 du virus de la grippe A</term><term>Sous-type H3N2 du virus de la grippe A</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">An avian-human reassortant influenza A virus deriving its genes coding for the hemagglutinin and neuraminidase from the human influenza A/Washington/897/80 (H3N2) virus and its six "internal" genes from the avian influenza A/Mallard/NY/6750/78 (H2N2) virus (i.e., a six-gene reassortant) was previously shown to be safe, infectious, nontransmissible, and immunogenic as a live virus vaccine in adult humans. Two additional six-gene avian-human reassortant influenza viruses derived from the mating of wild-type human influenza A/California/10/78 (H1N1) and A/Korea/1/82 (H3N2) viruses with the avian influenza A/Mallard/NY/78 virus were evaluated in seronegative (hemagglutination inhibition titer, less than or equal to 1:8) adult volunteers for safety, infectivity, and immunogenicity to determine whether human influenza A viruses can be reproducibly attenuated by the transfer of the six internal genes of the avian influenza A/Mallard/NY/78 virus. The 50% human infectious dose was 10(4.9) 50% tissue culture infectious doses for the H1N1 reassortant virus and 10(5.4) 50% tissue culture infectious doses for the H3N2 reassortant virus. Both reassortants were satisfactorily attenuated with only 5% (H1N1) and 2% (H3N2) of infected vaccines receiving less than 400 50% human infectious doses developing illness. Consistent with this level of attenuation, the magnitude of viral shedding after inoculation was reduced 100-fold (H1N1) to 10,000-fold (H3N2) compared with that produced by wild-type virus. The duration of virus shedding by vaccines was one-third that of controls receiving wild-type virus. At 40 to 100 50% human infectious doses, virus-specific immune responses were seen in 77 to 93% of volunteers. When vaccinees who has received 10(7.5) 50% tissue culture infectious doses of the H3N2 vaccine were experimentally challenged with a homologous wild-type human virus only 2 of 19 (11%) vaccinees became ill compared with 7 of 14 (50%) unvaccinated seronegative controls ( P < 0.025; protective efficacy, 79%). Thus, three different virulent human influenza A viruses have been satisfactorily attenuated by the acquisition of the six internal genes of the avian influenza A/Mallard/NY/78 virus. The observation that this donor virus can reproducibly attenuate human influenza A viruses indicates that avian-human influenza A reassortants should be further studied as potential live influenza A virus vaccines.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">3711273</PMID><DateCompleted><Year>1986</Year><Month>06</Month><Day>27</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0095-1137</ISSN><JournalIssue CitedMedium="Print"><Volume>23</Volume><Issue>5</Issue><PubDate><Year>1986</Year><Month>May</Month></PubDate></JournalIssue><Title>Journal of clinical microbiology</Title><ISOAbbreviation>J. Clin. Microbiol.</ISOAbbreviation></Journal><ArticleTitle>Evaluation of live avian-human reassortant influenza A H3N2 and H1N1 virus vaccines in seronegative adult volunteers.</ArticleTitle><Pagination><MedlinePgn>852-7</MedlinePgn></Pagination><Abstract><AbstractText>An avian-human reassortant influenza A virus deriving its genes coding for the hemagglutinin and neuraminidase from the human influenza A/Washington/897/80 (H3N2) virus and its six "internal" genes from the avian influenza A/Mallard/NY/6750/78 (H2N2) virus (i.e., a six-gene reassortant) was previously shown to be safe, infectious, nontransmissible, and immunogenic as a live virus vaccine in adult humans. Two additional six-gene avian-human reassortant influenza viruses derived from the mating of wild-type human influenza A/California/10/78 (H1N1) and A/Korea/1/82 (H3N2) viruses with the avian influenza A/Mallard/NY/78 virus were evaluated in seronegative (hemagglutination inhibition titer, less than or equal to 1:8) adult volunteers for safety, infectivity, and immunogenicity to determine whether human influenza A viruses can be reproducibly attenuated by the transfer of the six internal genes of the avian influenza A/Mallard/NY/78 virus. The 50% human infectious dose was 10(4.9) 50% tissue culture infectious doses for the H1N1 reassortant virus and 10(5.4) 50% tissue culture infectious doses for the H3N2 reassortant virus. Both reassortants were satisfactorily attenuated with only 5% (H1N1) and 2% (H3N2) of infected vaccines receiving less than 400 50% human infectious doses developing illness. Consistent with this level of attenuation, the magnitude of viral shedding after inoculation was reduced 100-fold (H1N1) to 10,000-fold (H3N2) compared with that produced by wild-type virus. The duration of virus shedding by vaccines was one-third that of controls receiving wild-type virus. At 40 to 100 50% human infectious doses, virus-specific immune responses were seen in 77 to 93% of volunteers. When vaccinees who has received 10(7.5) 50% tissue culture infectious doses of the H3N2 vaccine were experimentally challenged with a homologous wild-type human virus only 2 of 19 (11%) vaccinees became ill compared with 7 of 14 (50%) unvaccinated seronegative controls ( P < 0.025; protective efficacy, 79%). Thus, three different virulent human influenza A viruses have been satisfactorily attenuated by the acquisition of the six internal genes of the avian influenza A/Mallard/NY/78 virus. The observation that this donor virus can reproducibly attenuate human influenza A viruses indicates that avian-human influenza A reassortants should be further studied as potential live influenza A virus vaccines.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Snyder</LastName><ForeName>M H</ForeName><Initials>MH</Initials></Author><Author ValidYN="Y"><LastName>Clements</LastName><ForeName>M L</ForeName><Initials>ML</Initials></Author><Author ValidYN="Y"><LastName>Betts</LastName><ForeName>R F</ForeName><Initials>RF</Initials></Author><Author ValidYN="Y"><LastName>Dolin</LastName><ForeName>R</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Buckler-White</LastName><ForeName>A J</ForeName><Initials>AJ</Initials></Author><Author ValidYN="Y"><LastName>Tierney</LastName><ForeName>E L</ForeName><Initials>EL</Initials></Author><Author ValidYN="Y"><LastName>Murphy</LastName><ForeName>B R</ForeName><Initials>BR</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>N01 AI 12666</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>N01 AI 52577</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Clin Microbiol</MedlineTA><NlmUniqueID>7505564</NlmUniqueID><ISSNLinking>0095-1137</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D006389">Hemagglutinins, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014765">Viral Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.2.1.18</RegistryNumber><NameOfSubstance UI="D009439">Neuraminidase</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName><QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006389" MajorTopicYN="N">Hemagglutinins, Viral</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053118" MajorTopicYN="Y">Influenza A Virus, H1N1 Subtype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053122" MajorTopicYN="Y">Influenza A Virus, H3N2 Subtype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009980" MajorTopicYN="N">Influenza A virus</DescriptorName><QualifierName UI="Q000254" MajorTopicYN="N">growth & development</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009439" MajorTopicYN="N">Neuraminidase</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014765" MajorTopicYN="N">Viral Vaccines</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014779" MajorTopicYN="N">Virus Replication</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1986</Year><Month>5</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1986</Year><Month>5</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1986</Year><Month>5</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">3711273</ArticleId><ArticleId IdType="pmc">PMC268736</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>J Infect Dis. 1973 Oct;128(4):479-87</Citation><ArticleIdList><ArticleId IdType="pubmed">4743544</ArticleId></ArticleIdList></Reference><Reference><Citation>J Med Virol. 1985 Dec;17(4):325-35</Citation><ArticleIdList><ArticleId IdType="pubmed">4078559</ArticleId></ArticleIdList></Reference><Reference><Citation>Infect Immun. 1979 Feb;23(2):253-9</Citation><ArticleIdList><ArticleId IdType="pubmed">422240</ArticleId></ArticleIdList></Reference><Reference><Citation>J Biol Stand. 1980;8(3):233-42</Citation><ArticleIdList><ArticleId IdType="pubmed">7410447</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Microbiol. 1981 Mar;13(3):554-60</Citation><ArticleIdList><ArticleId IdType="pubmed">7240388</ArticleId></ArticleIdList></Reference><Reference><Citation>Infect Immun. 1982 Jun;36(3):1102-8</Citation><ArticleIdList><ArticleId IdType="pubmed">7095844</ArticleId></ArticleIdList></Reference><Reference><Citation>Infect Immun. 1982 Sep;37(3):1119-26</Citation><ArticleIdList><ArticleId IdType="pubmed">7129631</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 1982 Dec 24;218(4579):1330-2</Citation><ArticleIdList><ArticleId IdType="pubmed">6183749</ArticleId></ArticleIdList></Reference><Reference><Citation>Infect Immun. 1983 Jun;40(3):1044-51</Citation><ArticleIdList><ArticleId IdType="pubmed">6852910</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 1984 Mar 31;1(8379):705-8</Citation><ArticleIdList><ArticleId IdType="pubmed">6143042</ArticleId></ArticleIdList></Reference><Reference><Citation>J Infect Dis. 1984 May;149(5):814-5</Citation><ArticleIdList><ArticleId IdType="pubmed">6726006</ArticleId></ArticleIdList></Reference><Reference><Citation>J Infect Dis. 1984 May;149(5):816</Citation><ArticleIdList><ArticleId IdType="pubmed">6726007</ArticleId></ArticleIdList></Reference><Reference><Citation>J Infect Dis. 1984 Dec;150(6):841-50</Citation><ArticleIdList><ArticleId IdType="pubmed">6501928</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 1985 Mar;53(3):771-5</Citation><ArticleIdList><ArticleId IdType="pubmed">3973966</ArticleId></ArticleIdList></Reference><Reference><Citation>J Infect Dis. 1985 Jul;152(1):225-9</Citation><ArticleIdList><ArticleId IdType="pubmed">4008988</ArticleId></ArticleIdList></Reference><Reference><Citation>Virology. 1978 Feb;84(2):268-78</Citation><ArticleIdList><ArticleId IdType="pubmed">23604</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/H2N2V1/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000495 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 000495 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= H2N2V1
|flux= PubMed
|étape= Curation
|type= RBID
|clé= pubmed:3711273
|texte= Evaluation of live avian-human reassortant influenza A H3N2 and H1N1 virus vaccines in seronegative adult volunteers.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:3711273" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \
| NlmPubMed2Wicri -a H2N2V1
| This area was generated with Dilib version V0.6.33. |  |